Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives $66.00 Consensus Price Target from Brokerages

Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) have been given a consensus recommendation of “Moderate Buy” by the six ratings firms that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $63.00.

Several research firms recently issued reports on CLDX. Guggenheim raised their target price on Celldex Therapeutics from $72.00 to $90.00 and gave the stock a “buy” rating in a research note on Tuesday, February 27th. Wolfe Research assumed coverage on Celldex Therapeutics in a research report on Tuesday, June 11th. They set an “outperform” rating and a $51.00 price objective on the stock. HC Wainwright reaffirmed a “buy” rating and set a $80.00 price objective on shares of Celldex Therapeutics in a research report on Monday, June 3rd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $67.00 price objective on shares of Celldex Therapeutics in a research report on Friday, March 22nd.

Insider Activity

In other news, SVP Diane C. Young sold 45,000 shares of Celldex Therapeutics stock in a transaction that occurred on Friday, June 7th. The shares were sold at an average price of $35.26, for a total transaction of $1,586,700.00. Following the completion of the transaction, the senior vice president now directly owns 2,115 shares in the company, valued at $74,574.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, SVP Diane C. Young sold 45,000 shares of Celldex Therapeutics stock in a transaction that occurred on Friday, June 7th. The shares were sold at an average price of $35.26, for a total transaction of $1,586,700.00. Following the completion of the transaction, the senior vice president now directly owns 2,115 shares in the company, valued at $74,574.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Elizabeth Crowley sold 38,597 shares of Celldex Therapeutics stock in a transaction that occurred on Thursday, May 30th. The shares were sold at an average price of $33.64, for a total transaction of $1,298,403.08. Following the transaction, the vice president now owns 9,074 shares of the company’s stock, valued at $305,249.36. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 219,160 shares of company stock worth $7,501,489. Insiders own 3.80% of the company’s stock.

Hedge Funds Weigh In On Celldex Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the company. Wellington Management Group LLP raised its holdings in Celldex Therapeutics by 19.2% in the 4th quarter. Wellington Management Group LLP now owns 6,476,561 shares of the biopharmaceutical company’s stock worth $256,860,000 after acquiring an additional 1,044,728 shares during the last quarter. Vanguard Group Inc. raised its holdings in Celldex Therapeutics by 19.8% in the 1st quarter. Vanguard Group Inc. now owns 3,650,582 shares of the biopharmaceutical company’s stock worth $153,215,000 after acquiring an additional 604,251 shares during the last quarter. Eventide Asset Management LLC raised its holdings in Celldex Therapeutics by 126.9% in the 4th quarter. Eventide Asset Management LLC now owns 3,630,013 shares of the biopharmaceutical company’s stock worth $143,966,000 after acquiring an additional 2,030,013 shares during the last quarter. Kynam Capital Management LP raised its holdings in Celldex Therapeutics by 23.1% in the 3rd quarter. Kynam Capital Management LP now owns 3,200,000 shares of the biopharmaceutical company’s stock worth $88,064,000 after acquiring an additional 600,000 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD raised its holdings in Celldex Therapeutics by 631.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,087,208 shares of the biopharmaceutical company’s stock worth $129,571,000 after acquiring an additional 2,664,915 shares during the last quarter.

Celldex Therapeutics Price Performance

NASDAQ CLDX opened at $34.91 on Tuesday. The stock has a market capitalization of $2.30 billion, a PE ratio of -12.25 and a beta of 1.48. Celldex Therapeutics has a 1 year low of $22.11 and a 1 year high of $53.18. The business’s 50-day moving average is $37.66 and its 200 day moving average is $39.04.

Celldex Therapeutics (NASDAQ:CLDX) last posted its earnings results on Monday, May 6th. The biopharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.67) by $0.11. The company had revenue of $0.16 million for the quarter, compared to analysts’ expectations of $1.30 million. Celldex Therapeutics had a negative return on equity of 29.55% and a negative net margin of 2,385.57%. As a group, equities research analysts anticipate that Celldex Therapeutics will post -2.32 earnings per share for the current year.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.